Homare Eda

1.3k total citations · 1 hit paper
29 papers, 1.0k citations indexed

About

Homare Eda is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Homare Eda has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 20 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Homare Eda's work include Multiple Myeloma Research and Treatments (23 papers), Bone health and treatments (8 papers) and Protein Degradation and Inhibitors (8 papers). Homare Eda is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Bone health and treatments (8 papers) and Protein Degradation and Inhibitors (8 papers). Homare Eda collaborates with scholars based in United States, Japan and United Kingdom. Homare Eda's co-authors include Noopur Raje, Diana Cirstea, Loredana Santo, Teru Hideshima, Simon S. Jones, Kenneth C. Anderson, Matthew Jarpe, Walter C. Ogier, Neeharika Nemani and Andrew L. Kung and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Biochemical and Biophysical Research Communications.

In The Last Decade

Homare Eda

28 papers receiving 1.0k citations

Hit Papers

Preclinical activity, pharmacodynamic, and pharmacokineti... 2012 2026 2016 2021 2012 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
    2012 488 citations Loredana Santo, Teru Hideshima et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Homare Eda United States 13 815 480 364 73 62 29 1.0k
A M Martelli Italy 10 580 0.7× 191 0.4× 198 0.5× 68 0.9× 91 1.5× 17 785
Jo Ishizawa United States 18 664 0.8× 248 0.5× 252 0.7× 106 1.5× 89 1.4× 65 892
Thomas Strömberg Sweden 12 503 0.6× 214 0.4× 206 0.6× 40 0.5× 59 1.0× 15 744
Jennifer Lauchle United States 13 512 0.6× 203 0.4× 243 0.7× 31 0.4× 181 2.9× 23 833
Elisabeth A. Lasater United States 12 522 0.6× 146 0.3× 559 1.5× 51 0.7× 222 3.6× 21 963
Baohua Sun United States 20 893 1.1× 268 0.6× 260 0.7× 52 0.7× 114 1.8× 41 1.2k
Louise Barys Switzerland 8 328 0.4× 157 0.3× 139 0.4× 69 0.9× 80 1.3× 12 575
Monica Minischetti Italy 7 615 0.8× 471 1.0× 530 1.5× 100 1.4× 133 2.1× 8 1.1k
Leila R. Martins Portugal 14 652 0.8× 312 0.7× 256 0.7× 45 0.6× 193 3.1× 21 1.1k
Lolita Banerji United Kingdom 13 753 0.9× 286 0.6× 264 0.7× 59 0.8× 211 3.4× 15 1.1k

Countries citing papers authored by Homare Eda

Since Specialization
Citations

This map shows the geographic impact of Homare Eda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Homare Eda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Homare Eda more than expected).

Fields of papers citing papers by Homare Eda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Homare Eda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Homare Eda. The network helps show where Homare Eda may publish in the future.

Co-authorship network of co-authors of Homare Eda

This figure shows the co-authorship network connecting the top 25 collaborators of Homare Eda. A scholar is included among the top collaborators of Homare Eda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Homare Eda. Homare Eda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Siu, Ka Tat, Janani Ramachandran, Andrew J. Yee, et al.. (2016). Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. 31(8). 1760–1769. 67 indexed citations
3.
Eda, Homare, Loredana Santo, G. David Roodman, & Noopur Raje. (2016). Bone Disease in Multiple Myeloma. Cancer treatment and research. 169. 251–270. 24 indexed citations
4.
Eda, Homare, Loredana Santo, Marc N. Wein, et al.. (2016). Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. Journal of Bone and Mineral Research. 31(6). 1225–1234. 77 indexed citations
5.
Siu, Ka Tat, Janani Ramachandran, Andrew J. Yee, et al.. (2016). Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma. Blood. 128(22). 3320–3320. 2 indexed citations
6.
Mishima, Yuko, Loredana Santo, Homare Eda, et al.. (2015). Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death. British Journal of Haematology. 169(3). 423–434. 87 indexed citations
7.
Siu, Ka Tat, Homare Eda, Loredana Santo, et al.. (2015). Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma. Blood. 126(23). 4255–4255. 13 indexed citations
8.
Cirstea, Diana, Loredana Santo, Teru Hideshima, et al.. (2014). Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics. 13(11). 2489–2500. 24 indexed citations
9.
10.
Cirstea, Diana, Teru Hideshima, Loredana Santo, et al.. (2013). Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 27(12). 2366–2375. 47 indexed citations
11.
Pozzi, Samantha, Mariateresa Fulciniti, Yan Hua, et al.. (2013). In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 53(2). 487–496. 56 indexed citations
12.
Santo, Loredana, Sonia Vallet, Mariateresa Fulciniti, et al.. (2013). Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia. 27(8). 1715–1721. 34 indexed citations
13.
Mishima, Yuko, Loredana Santo, Diana Cirstea, et al.. (2013). Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma. Blood. 122(21). 4431–4431. 2 indexed citations
14.
Santo, Loredana, Teru Hideshima, Andrew L. Kung, et al.. (2012). Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 119(11). 2579–2589. 488 indexed citations breakdown →
15.
16.
Eda, Homare, Katsuhiko Aoki, Yutaka Okawa, et al.. (2010). The proteasome inhibitor bortezomib inhibits FGF‐2‐induced reduction of TAZ levels in osteoblast‐like cells. European Journal Of Haematology. 85(1). 68–75. 11 indexed citations
17.
Vallet, Sonia, Kishan Patel, Diana Cirstea, et al.. (2010). Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy. Blood. 116(21). 4075–4075. 2 indexed citations
18.
Pozzi, Samantha, Diana Cirstea, Loredana Santo, et al.. (2010). CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies. Blood. 116(21). 2999–2999. 2 indexed citations
19.
Eda, Homare, Katsuhiko Aoki, Keishi Marumo, Katsuyuki Fujii, & Kiyoshi Ohkawa. (2007). FGF-2 signaling induces downregulation of TAZ protein in osteoblastic MC3T3-E1 cells. Biochemical and Biophysical Research Communications. 366(2). 471–475. 26 indexed citations
20.
Eda, Homare. (1987). [Isolation and characterization of osteonectin from rabbit alveolar bone].. PubMed. 21(4). 555–66. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A M Martelli Breakdown of academic impact, for papers by Jo Ishizawa Breakdown of academic impact, for papers by Thomas Strömberg Breakdown of academic impact, for papers by Jennifer Lauchle Breakdown of academic impact, for papers by Elisabeth A. Lasater Breakdown of academic impact, for papers by Baohua Sun Breakdown of academic impact, for papers by Louise Barys Breakdown of academic impact, for papers by Monica Minischetti Breakdown of academic impact, for papers by Leila R. Martins Breakdown of academic impact, for papers by Lolita Banerji
Rankless by CCL
2026